Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Elan
 More »

  • Elan Bets $1B on Theravance/GSK Respiratory Drugs
    Theravance and Elan have entered into a $1 billion royalty participation agreement through ... Under the terms of the agreement, Elan will make a one-time cash payment to Theravance for ...
    5-13-2013
  • GEN | Biolinks
    ... Development Corporation of Utah Economic Development Partnership of Alabama EFEX Eisai Elan Elchrom Scientific Elevation Pharmaceuticals Eleven Biotherapeutics Eli Lilly and ...
  • Tug of War Continues: Elan vs. Royalty
    The latest development in a two-month tug of war between Elan and Royalty Pharma has Elan flat-out rejecting Royalty's most recent offer for the company. The battle has revolved ...
    4-22-2013
  • Royalty Makes $7.3B Play for Elan
    In the midst of an ongoing takeover battle between Royalty Pharma and Elan, Echo Pharma Acquisition (Royalty Pharma) today made a firm, all-cash offer for Elan potentially valued ...
    4-15-2013
  • Clock Ticking in Elan Takeover Battle
    Pharma) to make a formal offer for Elan or declare it will give up plans to buy ... generated by biopharmaceuticals-angered Elan when it announced plans February 22 to ...
    4-3-2013
  • Elan Cool to Royalty Pharma Offer
    in the multiple sclerosis drug Tysabri, Elan has suddenly attracted a would-be suitor ... today it was offering $6.5 billion for Elan, or $11 per American depository receipt ...
    2-25-2013
  • $3.25B Tysabri Deal a Win-Win for Biogen Idec, Elan
    sclerosis drug it co-developed with Elan, boosts Biogen Idec's presence in MS drugs ... of this business collaboration provides Elan with significant strategic flexibility. ...
    2-6-2013
  • Progressive MS Therapy Sparks Deal Worth Up to $225M
    Merck had hoped to roll out a new product given increasing competition for its injectable MS drug Rebif. Last month, however, Biogen Idec and Elan last month submitted applications ...
    2-5-2013
  • Elan Severs Ties with Alkermes
    Elan, through its wholly owned subsidiary, Elan Science Three, agreed to sell all of its remaining 7,750,000 ordinary shares of Alkermes through Jefferies & Company. The sale is ...
    2-1-2013
  • Bittersweet News at Biogen Idec
    Its Q4 2012 revenues increased 10% year-over-year to about $295.2 million from $269.4 million a year earlier. Biogen Idec co-markets Tysabri with Elan. Avonex (interferon beta-1a) ...
    1-28-2013
  • Acorda, Elan Wrap Up Their Deals
    In a separate deal, Elan announced completion of a spin-out of what it termed a ... NASDAQ. Prothena rises out of the ashes of Elan, which shut down its South San Francisco ...
    12-21-2012
  • Top 25 Biotech Companies
    ... Cap: $3.32 billion (7/15: 111,827,290 shares * price $29.69) % Change: 61.1% #15. Elan 2012 Market Cap: $8.63 billion (6/30: 591.3 million shares *price $14.59) 2011 Market ...
    8-17-2012
  • The Big Idea for 2009 as Discussed at J.P. Morgan
    CEPH acquired Ception this month, which has mAb product for treatment of pediatric eosinophilic esophagitis. 30% of Cephalon sales are new products. Elan(ELN)-The $1 billion Irish ...
    8-13-2012
  • Elan to Cut Loose Its Discovery Subsidiary
    Elan says it plans to spin out its discovery science and Neotope Biosciences antibody therapeutics firm to shareholders. Elan itself will continue developing its Biogen ...
    8-13-2012
  • Life Science Market Q3 2009-Summer rally sparked by deals
    Medarex for $2.37B JNJ bought Cougar for $1B, 18% of Crucell for $441M and 18% of Elan for $885M Sanofi bought Merial for $4B The vaccine area was largely abandoned by large ...
    8-9-2012

  • Journal Articles

  • A High-Throughput Assay for Evaluating State Dependence and Subtype...
    Ge Dai, Rodolfo J. Haedo, Vivien A. Warren, Kevin S. Ratliff, Randal M. Bugianesi, Alison Rush, Mark E. Williams, James Herrington, McHardy M. Smith, Owen B. McManus, Andrew M. Swensen
    ASSAY and Drug Development Technologies
    The Cav2.2-selective peptide blocker ziconotide (Prialt®, Elan Pharmaceuticals, Dublin, Ireland) has proven efficacious in pain relief, but has a poor therapeutic index and ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll